<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330589</url>
  </required_header>
  <id_info>
    <org_study_id>2010-56-LGH</org_study_id>
    <nct_id>NCT01330589</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort</brief_title>
  <acronym>INDUCE-it</acronym>
  <official_title>The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lancaster General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. G. Barsumian Memorial Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Louise von Hess Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lancaster General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether patients post PCI receiving clopidogrel who
      are carriers of at least one CYP 2C19 loss-of-function allele may achieve improved
      pharmacodynamic efficacy of clopidogrel when treated with the CYP 2C19 enzyme inducing agent,
      St. John's wort, as compared with placebo.

      Hypothesis

        1. Reduced platelet reactivity is present in patients receiving St. John's wort as compared
           to placebo when utilized in combination with clopidogrel

        2. The combination or St. John's wort and clopidogrel results in enhanced platelet
           inhibition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective The purpose of this study is to evaluate whether patients post PCI receiving
      clopidogrel who are carriers of at least one CYP 2C19 loss-of-function allele may achieve
      improved pharmacodynamic efficacy of clopidogrel when treated with the CYP 2C19 enzyme
      inducing agent, St. John's wort, as compared with placebo.

      Specific Aims

        1. To identify the difference in platelet reactivity in patients receiving St. John's wort
           or placebo

        2. To characterize the difference in platelet inhibition in patients receiving St. John's
           wort or placebo

      Hypothesis

        1. Reduced platelet reactivity is present in patients receiving St. John's wort as compared
           to placebo when utilized in combination with clopidogrel

        2. The combination or St. John's wort and clopidogrel results in enhanced platelet
           inhibition

      Study Design The study is a prospective, randomized, double-blind, placebo-controlled,
      cross-over study of patients post PCI who require dual-antiplatelet therapy with aspirin and
      clopidogrel. Approximately 84 patients will be enrolled and undergo pharmacogenetic testing
      to assess clopidogrel responsiveness utilizing CYP P450 2C19 genotyping (Plavitest®). Based
      upon an assumption of 30% genetic non-responsiveness and a dropout rate of 20%, to achieve a
      final sample size of 20 subjects in the randomized crossover portion of the study, the
      investigators need to enroll approximately 84 subjects. Patients identified as carriers of at
      least one CYP 2C19 loss-of-function allele (i.e. clopidogrel reduced-metabolizers) will
      remain in the study and be randomly assigned to receive placebo or St. John's wort. Patients
      not carrying a CYP 2C19 loss-of-function allele (i.e. clopidogrel normal metabolizers) will
      not require any further follow-up as these patients are considered to display a normal
      response to clopidogrel. On day 7 following the initiation of the study drug, platelet
      function testing will be performed. Following a 7 day washout period, patients will be
      crossed over into the other study group to receive 7 days of study medication. On day 21, the
      patients will undergo platelet function testing and the study medication will be
      discontinued.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Inability to enroll subjects and changes in standard of care for PCI
  </why_stopped>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean platelet reactivity (as measured in platelet reactivity units) on day 7 and day 21</measure>
    <time_frame>Day 7 and Day 21</time_frame>
    <description>The investigators are comparing the mean platelet reactivity (as measured in platelet reactivity units) within subjects (treatment effect) between placebo and St. Johns Wort. In addition we will be assessing the period effect (difference between those getting treatment AB - placebo/St. Johns Wort and those getting treatment BA - St. Johns Wort/placebo).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>AB: Placebo (A); St. Johns Wort (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive placebo for 7 days, 7 days washout and 7 days of St. Johns Wort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA: St. Johns Wort (B); Placebo (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive St. Johns Wort for 7 days, 7 days washout and 7 days of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Non-active placebo for 7 days: PO/TID</description>
    <arm_group_label>AB: Placebo (A); St. Johns Wort (B)</arm_group_label>
    <arm_group_label>BA: St. Johns Wort (B); Placebo (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>St. Johns Wort</intervention_name>
    <description>For 7 days: 300mg PO/TID</description>
    <arm_group_label>AB: Placebo (A); St. Johns Wort (B)</arm_group_label>
    <arm_group_label>BA: St. Johns Wort (B); Placebo (A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age 18 or older

          -  Patients with a history of ACS and/or who receive PCI with stent placement at
             Lancaster General Hospital requiring dual antiplatelet therapy with aspirin and
             clopidogrel.

        Exclusion Criteria:

          -  Patients with active or any known history of bleeding such as gastrointestinal,
             intracranial, or any other bleeding diathesis

          -  History of major surgery in the last year (any surgical procedure that involves
             general anesthesia or respiratory assistance)

          -  Clinical findings associated with an increased risk of bleeding at the judgment of the
             investigator

          -  Patients actively receiving anticoagulation therapy

          -  Hemoglobin &lt; 10 g/dL

          -  Platelets &lt; 150,000/mm3

          -  Known hepatic dysfunction

          -  History of intracranial malignancy or stroke

          -  Patients receiving thienopyridines chronically prior to PCI

          -  Concurrent use of CYP P450 2C19 substrates, or inhibiting/ inducing medications with
             the exception of proton pump inhibitors

          -  Illicit drug or alcohol abuse

          -  Daily treatment with nonsteroidal anti-inflammatory drugs or cyclooxygenase-2
             inhibitors

          -  Allergy to St. Johns wort or lactose

          -  Patients expected to discontinue dual antiplatelet therapy prior to completion of the
             study protocol

          -  Patients unable to adhere to the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy M Makkar, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lancaster General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roy S Small, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lancaster General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rupal P Dumasia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lancaster General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jill A Rebuck, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lancaster General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael A Horst, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lancaster General Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yee M Lee, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lancaster General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard D Paoletti, RPh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lancaster General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494-502. Erratum in: N Engl J Med 2001 Nov 15;345(20):1506. N Engl J Med 2001 Dec 6;345(23):1716.</citation>
    <PMID>11519503</PMID>
  </reference>
  <reference>
    <citation>Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Nov 20;288(19):2411-20. Erratum in: JAMA. 2003 Feb 26;289(8):987..</citation>
    <PMID>12435254</PMID>
  </reference>
  <reference>
    <citation>Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-17. Epub 2006 Mar 12.</citation>
    <PMID>16531616</PMID>
  </reference>
  <reference>
    <citation>Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T, Mitsudo K, Miyazaki S, Yamaguchi T, Hiyoshi E, Nishimura E, Isshiki T; RESTART Investigators. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation. 2010 Jul 6;122(1):52-61. doi: 10.1161/CIRCULATIONAHA.109.903955. Epub 2010 Jun 21.</citation>
    <PMID>20566955</PMID>
  </reference>
  <reference>
    <citation>Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, Maffrand JP. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992 Aug 4;44(3):527-32.</citation>
    <PMID>1510701</PMID>
  </reference>
  <reference>
    <citation>Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22;360(4):354-62. doi: 10.1056/NEJMoa0809171. Epub 2008 Dec 22.</citation>
    <PMID>19106084</PMID>
  </reference>
  <reference>
    <citation>Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363-75. doi: 10.1056/NEJMoa0808227. Epub 2008 Dec 22.</citation>
    <PMID>19106083</PMID>
  </reference>
  <reference>
    <citation>Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J, Chen GL, Liu J, Tang ZR, An W, Li Q, Wang D, Zhou HH. The influence of St John's Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol. 2004 Jun;44(6):577-81.</citation>
    <PMID>15145964</PMID>
  </reference>
  <reference>
    <citation>Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 2004 May 27;(343):1-19.</citation>
    <PMID>15188733</PMID>
  </reference>
  <reference>
    <citation>Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL, Wang D, Zhong XY, Zhou HH. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004 Mar;75(3):191-7.</citation>
    <PMID>15001970</PMID>
  </reference>
  <reference>
    <citation>Lau W, Carville D, Guyer K, Neer C. St. John's wort enhances the platelet inhibitor effect of clopidogrel in clopidogrel &quot;resistant&quot; healthy volunteers. J Am Coll Cardiol 2005;4:382A(abstract).</citation>
  </reference>
  <reference>
    <citation>Lau WC, Welch TD, Shields TA, Rubenfire M, Gurbel PA. The effect of St. John's wort on the pharmacodynamic efficacy of clopidogrel in hyporesponsive volunteers. J Am Coll Cardiol 2010;55:A171(abstract).</citation>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lancaster General Hospital</investigator_affiliation>
    <investigator_full_name>Michael A. Horst, PhD, MPHS, MS</investigator_full_name>
    <investigator_title>Director of Research</investigator_title>
  </responsible_party>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>St. John's Wort</keyword>
  <keyword>CYP 2C19 loss-of-function allele</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

